SE9304060D0 - Sätt att selektera specifika bakteriofager - Google Patents

Sätt att selektera specifika bakteriofager

Info

Publication number
SE9304060D0
SE9304060D0 SE9304060A SE9304060A SE9304060D0 SE 9304060 D0 SE9304060 D0 SE 9304060D0 SE 9304060 A SE9304060 A SE 9304060A SE 9304060 A SE9304060 A SE 9304060A SE 9304060 D0 SE9304060 D0 SE 9304060D0
Authority
SE
Sweden
Prior art keywords
phage
pct
molecule
protein
methods
Prior art date
Application number
SE9304060A
Other languages
English (en)
Swedish (sv)
Inventor
Carl A K Borrebaeck
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Priority to SE9304060A priority Critical patent/SE9304060D0/xx
Publication of SE9304060D0 publication Critical patent/SE9304060D0/xx
Priority to PCT/SE1994/001166 priority patent/WO1995016027A1/en
Priority to DE69417446T priority patent/DE69417446T2/de
Priority to US08/640,792 priority patent/US5712089A/en
Priority to EP95903485A priority patent/EP0739413B1/en
Priority to ES95903485T priority patent/ES2132601T3/es
Priority to JP51614195A priority patent/JP3574135B2/ja
Priority to CA002178205A priority patent/CA2178205A1/en
Priority to AT95903485T priority patent/ATE178092T1/de
Priority to DK95903485T priority patent/DK0739413T3/da
Priority to AU12521/95A priority patent/AU686292B2/en
Priority to GR990401295T priority patent/GR3030210T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SE9304060A 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager SE9304060D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager
AU12521/95A AU686292B2 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
EP95903485A EP0739413B1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
DE69417446T DE69417446T2 (de) 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen
US08/640,792 US5712089A (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
PCT/SE1994/001166 WO1995016027A1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
ES95903485T ES2132601T3 (es) 1993-12-06 1994-12-05 Procedimiento para la seleccion de bacteriofagos especificos.
JP51614195A JP3574135B2 (ja) 1993-12-06 1994-12-05 特異的バクテリオファージの選択方法
CA002178205A CA2178205A1 (en) 1993-12-06 1994-12-05 Method of selecting specific bacteriophages
AT95903485T ATE178092T1 (de) 1993-12-06 1994-12-05 Methode zur selektion spezifischer bakteriophagen
DK95903485T DK0739413T3 (da) 1993-12-06 1994-12-05 Fremgangsmåde til udvælgelse af specifikke bakteriofager
GR990401295T GR3030210T3 (en) 1993-12-06 1999-05-13 Method of selecting specific bacteriophages

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager

Publications (1)

Publication Number Publication Date
SE9304060D0 true SE9304060D0 (sv) 1993-12-06

Family

ID=20392016

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9304060A SE9304060D0 (sv) 1993-12-06 1993-12-06 Sätt att selektera specifika bakteriofager

Country Status (12)

Country Link
US (1) US5712089A (da)
EP (1) EP0739413B1 (da)
JP (1) JP3574135B2 (da)
AT (1) ATE178092T1 (da)
AU (1) AU686292B2 (da)
CA (1) CA2178205A1 (da)
DE (1) DE69417446T2 (da)
DK (1) DK0739413T3 (da)
ES (1) ES2132601T3 (da)
GR (1) GR3030210T3 (da)
SE (1) SE9304060D0 (da)
WO (1) WO1995016027A1 (da)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164395T1 (de) * 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
SE9503151D0 (sv) * 1995-09-13 1995-09-13 Bioinvent Internatioal Ab Combined ligand and receptor display
SE506771C2 (sv) * 1996-02-06 1998-02-09 Gotpat 105 Ab Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6497874B1 (en) 1997-02-05 2002-12-24 Maardh Sven Recombinant phages
GB9716900D0 (en) * 1997-08-08 1997-10-15 Bioinvent Int Ab Method for selecting phage displaying ligand binders
EP1518927A3 (en) * 1998-02-11 2005-06-22 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
MXPA00007889A (es) * 1998-02-11 2002-09-18 Maxygen Inc Optimizacion de las propiedades inmunomoduladoras de las vacunas geneticas.
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
EP1100890A2 (en) 1998-07-27 2001-05-23 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
CA2393869A1 (en) * 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
DK2857516T3 (da) 2000-04-11 2017-08-07 Genentech Inc Multivalente antistoffer og anvendelser herfor
US6686154B2 (en) * 2000-06-05 2004-02-03 Zyomyx, Inc. Screening of phage displayed peptides without clearing of the cell culture
CA2415473A1 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US7262012B2 (en) * 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
EP2891666B1 (en) 2002-10-16 2017-06-28 Purdue Pharma L.P. Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
GB2400851B (en) * 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1789453A2 (en) * 2004-05-18 2007-05-30 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
PL3031825T3 (pl) 2008-03-14 2020-02-28 Allergan, Inc. Immunologiczne oznaczenie aktywności toksyny botulinowej serotypu a
CN102316894A (zh) 2008-06-20 2012-01-11 惠氏有限责任公司 来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
CA2733642A1 (en) 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
JP5723774B2 (ja) * 2008-09-05 2015-05-27 プレジデント アンド フェローズ オブ ハーバード カレッジ タンパク質および核酸の連続的指向性進化
RU2543650C2 (ru) 2009-03-13 2015-03-10 Аллерган, Инк. Иммунологические тесты на активность эндопептидаз с измененной нацеленностью
JP2013540991A (ja) * 2010-08-27 2013-11-07 ユニバーシティ・オブ・チューリッヒ 炎症および／または心血管疾患における新規診断および治療標的
CA2825370A1 (en) * 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
CA2907234A1 (en) 2013-03-15 2014-09-25 Altria Client Services Llc Bacteriophage and methods of making and using
US9944693B2 (en) 2013-12-08 2018-04-17 Peptcell Limited HIV antigens and antibodies and compositions, uses and methods thereof
ES2920677T3 (es) 2013-12-24 2022-08-08 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-VISTA
US10179911B2 (en) 2014-01-20 2019-01-15 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
WO2016123427A1 (en) 2015-01-29 2016-08-04 Altria Client Services Llc Bacteriophage and methods of using
US10357056B2 (en) 2015-01-29 2019-07-23 Altria Client Services Llc Endolysin from bacteriophage against Geobacillus and methods of using
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
TWI756204B (zh) 2016-02-12 2022-03-01 比利時商楊森製藥公司 抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
BR112018069776A2 (pt) 2016-03-29 2019-02-05 Janssen Biotech Inc tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR20190059305A (ko) 2016-09-30 2019-05-30 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
AU2017362222A1 (en) 2016-11-16 2019-05-30 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
JP2020506947A (ja) 2017-02-07 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College EVOLUTION OF ARNT SYNTHÉTASES
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
JP2021530697A (ja) 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
CA3160103A1 (en) 2018-09-24 2020-04-02 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
EP3897722A4 (en) 2018-12-18 2022-09-14 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
CA3126654A1 (en) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
MX2021008871A (es) 2019-01-23 2021-08-19 Janssen Biotech Inc Composiciones de anticuerpos anti-tnf para usarse en metodos para el tratamiento de la artritis psoriasica.
EP3938391A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
CA3133395A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
US20220153829A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Methods for Producing Anti-TNF Antibody Compositions
JP2022525179A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための産生方法
CN113853385A (zh) 2019-03-18 2021-12-28 詹森生物科技公司 用抗il12/il23抗体治疗儿科受试者的银屑病的方法
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
KR20220030952A (ko) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2020245676A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
JP2024510588A (ja) 2021-03-12 2024-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
US20220298236A1 (en) 2021-03-12 2022-09-22 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
US20230040065A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
WO2023281466A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
CN117957251A (zh) 2021-07-09 2024-04-30 詹森生物科技公司 用于制备抗tnf抗体组合物的制造方法
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2023095000A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0614989A1 (en) * 1993-02-17 1994-09-14 MorphoSys AG A method for in vivo selection of ligand-binding proteins

Also Published As

Publication number Publication date
EP0739413B1 (en) 1999-03-24
AU1252195A (en) 1995-06-27
GR3030210T3 (en) 1999-08-31
ATE178092T1 (de) 1999-04-15
DK0739413T3 (da) 1999-10-11
DE69417446D1 (de) 1999-04-29
JP3574135B2 (ja) 2004-10-06
JPH09506000A (ja) 1997-06-17
CA2178205A1 (en) 1995-06-15
WO1995016027A1 (en) 1995-06-15
DE69417446T2 (de) 1999-09-02
AU686292B2 (en) 1998-02-05
ES2132601T3 (es) 1999-08-16
EP0739413A1 (en) 1996-10-30
US5712089A (en) 1998-01-27

Similar Documents

Publication Publication Date Title
SE9304060D0 (sv) Sätt att selektera specifika bakteriofager
ATE169058T1 (de) Gegen cd3 gerichtete antikörper
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
WO1999062526A3 (en) Use of genetically engineered antibodies to cd38 to treat multiple myeloma
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE69833106D1 (de) Antigene fusionsproteine, die gal-alpha-1,3-gal-epitope enthalten.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
DK0626861T3 (da) Behandling af astma.
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
DE69622259T2 (de) Cd40 bindendes protein zur stimulierung der immunantwort
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
DK0580672T3 (da) Syntetisk CDw52-(CAMPATH-1)-peptidantigen
DE69200460D1 (de) Agglutinationskomplex zum Nachweis von Blutgruppen.
HUT69623A (en) Use of endotheli- leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma
ATE328088T1 (de) Transketolase-verwandtes protein
KR890009417A (ko) 모노크로날 항체의 제조방법 및 그것의 이용방법
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
DK0597043T3 (da) Porcine adipocytantigener og deres anvendelse til immunologisk bekæmpelse af fedt
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
GB2333295A (en) Modified protein G and fragments thereof
IT1267667B1 (it) Metodo per il dosaggio di una variante della proteina alfa-1-antitripsina